Eli Lilly & Co LLY Stock Forecast
AI-powered price prediction and analysis for Eli Lilly & Co · Alpha · vs marketSwitch to Total
See LLY's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Eli Lilly & Co
Eli Lilly & Co (LLY) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where LLY sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| LLY Eli Lilly & Co | $1.28T | 44.3x | |
| JNJ Johnson & Johnson | $664.95B | 42.0x | |
| ABBV Abbvie Inc. | $514.78B | 44.6x | |
| MRK Merck & Co., Inc. | $362.01B | 151.3x | |
| NVS Novartis Ag | $310.17B | 9.8x | |
| AZN Astrazeneca Plc | $288.97B | 13.5x | |
| ABT Abbott Laboratories | $191.15B | 38.8x | |
| NVO Novo Nordisk A S | $179.14B | 3.0x | |
| PFE Pfizer Inc | $167.51B | 37.2x | |
| VRTX Vertex Pharmaceuticals Inc / … | $137.50B | 34.9x | |
| BMY Bristol Myers Squibb Co | $127.02B | 13.8x | |
| SNY Sanofi | $115.97B | – | |
| GSK Gsk Plc | $101.54B | 5.6x | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | 20.0x | |
| TAK Takeda Pharmaceutical Co Ltd | $66.19B | 6.4x | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | 41.0x | |
| ONC Beone Medicines Ltd. | $46.26B | 1130.5x | |
| GMAB Genmab A/S | $34.50B | 2.2x | |
| ZTS Zoetis Inc. | $33.93B | 14.0x | |
| RPRX Royalty Pharma Plc | $28.82B | 47.1x | |
| ROIV Roivant Sciences Ltd. | $26.45B | – | |
| INSM Insmed Inc | $25.10B | – | |
| UTHR United Therapeutics Corp | $24.11B | 21.2x | |
| VTRS Viatris Inc | $22.87B | – | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.89B | 7.3x | |
| ASND Ascendis Pharma A/S | $16.86B | – | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | 77.5x | |
| BBIO Bridgebio Pharma, Inc. | $14.47B | – | |
| SMMT Summit Therapeutics Inc. | $13.03B | – | |
| ELAN Elanco Animal Health Inc | $12.86B | – | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | 16.4x | |
| BMRN Biomarin Pharmaceutical Inc | $10.85B | 560.3x | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.24B | – | |
| TGTX Tg Therapeutics, Inc. | $9.20B | 21.9x | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | – | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | 33.6x | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.22B | – | |
| CORT Corcept Therapeutics Inc | $7.87B | 43.6x | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | – | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | – | |
| ALKS Alkermes Plc. | $7.70B | 44.6x | |
| ABVX Abivax S.A. | $7.50B | – | |
| CYTK Cytokinetics Inc | $7.46B | – | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.37B | 86.9x | |
| AXSM Axsome Therapeutics, Inc. | $6.93B | – | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | – | |
| IONS Ionis Pharmaceuticals Inc | $6.55B | – | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.43B | 61.0x | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | 116.9x | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.07B | – | |
| BLTE Belite Bio, Inc | $6.07B | – | |
| MANE Veradermics, Inc | $5.80B | – | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | – | |
| COGT Cogent Biosciences, Inc. | $5.49B | – | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | – | |
| ERAS Erasca, Inc. | $5.04B | – | |
| EWTX Edgewise Therapeutics, Inc. | $4.89B | 5.4x | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.81B | – | |
| TVTX Travere Therapeutics, Inc. | $4.44B | – | |
| LEGN Legend Biotech Corp | $4.33B | – |
FAQ
Is Eli Lilly & Co a good stock to buy?
Our AI analyzes Eli Lilly & Co daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Eli Lilly & Co predictions?
For LLY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 34.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 6.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Eli Lilly & Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Eli Lilly & Co? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.